Fabris Chiara, Kovatchev Boris
Center for Diabetes Technology, Department of Psychiatry and Neurobehavioral Sciences, School of Medicine, University of Virginia, Charlottesville, VA, USA.
J Diabetes Sci Technol. 2024 Aug 24:19322968241274786. doi: 10.1177/19322968241274786.
The objective of this work is to document performance of automated insulin delivery (AID) during real-life use in type 2 diabetes (T2D).
A retrospective analysis was performed of continuous glucose monitoring and insulin delivery data from 796 individuals with T2D, who transitioned from 1-month predictive low-glucose suspend (PLGS) use to 3-month AID use, in real-life settings. Primary outcome was change of time in range (TIR = 70-180 mg/dL) from PLGS to AID. Secondary outcomes included time above/below range (TAR/TBR) and total daily insulin (TDI).
Compared with PLGS, AID increased TIR on average from 63.2% to 72.6%, decreased TAR from 36.2% to 26.8%, and increased TDI from 70.2 to 76.3 U (all < .001), without significant change to TBR. Glycemic improvements were more pronounced in those with worse glycemic control during PLGS use ( < .001).
Real-life use of AID led to a rapid and sustained improvement of glycemic control in individuals with T2D.
本研究的目的是记录2型糖尿病（T2D）患者在实际使用自动胰岛素给药（AID）期间的表现。
对796例T2D患者的连续血糖监测和胰岛素给药数据进行回顾性分析，这些患者在实际环境中从使用1个月的预测性低血糖暂停（PLGS）过渡到使用3个月的AID。主要结局是从PLGS到AID期间血糖在目标范围内的时间（TIR = 70 - 180 mg/dL）的变化。次要结局包括高于/低于目标范围的时间（TAR/TBR）和每日总胰岛素用量（TDI）。
与PLGS相比，AID使TIR平均从63.2%提高到72.6%，TAR从36.2%降至26.8%，TDI从70.2 U增加到76.3 U（均P <.001），而TBR无显著变化。在PLGS使用期间血糖控制较差的患者中，血糖改善更为明显（P <.001）。
在T2D患者中，实际使用AID可导致血糖控制迅速且持续改善。
